ALS Investment Fund is a venture capital fund managed by SUNU Ventures that invests in biotech companies developing drugs and diagnostics for neurodegenerative diseases, with a particular focus on ALS. Based in Amsterdam, the fund backs early-stage companies entering proof-of-concept and Phase 1/2 clinical investigations.
56% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-a (67% of deals). Average disclosed round size is $62.9M (across 7 rounds with reported amounts).
Portfolio
7
Fund Size
$100M
Top Stage
Series A
Last 12 Mo
0
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
9 investments
Top Co-Investors
EQT Life Sciences4 shared
MRL Ventures Fund3 shared
BioGeneration Ventures3 shared
Forbion3 shared
Insight Partners3 shared
SciFi VC2 shared
Founders Fund2 shared
Leaps by Bayer1 shared
Apollo Health Ventures1 shared
Joyance Partners1 shared
Sanofi Ventures1 shared
Dolby Family Ventures1 shared
Dementia Discovery Fund1 shared
Amgen Ventures1 shared
Mission BioCapital1 shared
Polaris Partners1 shared
INKEF Capital1 shared
Slow Ventures1 shared
OS Fund1 shared
Last updated: 20 October 2026